GlobeNewswire: The Greater Cannabis Company, Inc. Contains the last 10 of 37 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:39:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/27/2835913/0/en/GCANRx-Announces-Completion-of-Preclinical-Study-for-Neuropsychiatric-Cannabinoid-Therapy.html?f=22&fvtc=4&fvtv=49683GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy2024-02-27T12:45:00Z<![CDATA[BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy.]]>https://www.globenewswire.com/news-release/2023/09/21/2747278/0/en/GCANRx-Featured-in-American-Journal-of-Endocannabinoid-Medicine.html?f=22&fvtc=4&fvtv=49683GCANRx Featured in American Journal of Endocannabinoid Medicine2023-09-21T12:29:57Z<![CDATA[BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that the Company and its scientific advisor, Dr. Adi Aran, has been featured in the American Journal of Endocannabinoid Medicine (AJEM).]]>https://www.globenewswire.com/news-release/2023/07/05/2699515/0/en/GCANRx-Announces-Approval-of-Phase-II-Clinical-Trial-to-Treat-Autism-Related-Spectrum-Disorders.html?f=22&fvtc=4&fvtv=49683GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders2023-07-05T12:33:34Z<![CDATA[BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that it has been granted final approval for its double blind, placebo controlled Phase II Clinical Trial for the treatment of Autism Spectrum Disorder (ASD) from the Israel Ministry of Health.]]>https://www.globenewswire.com/news-release/2022/10/07/2530316/0/en/GCANRx-Announces-Submission-of-Phase-2-Clinical-Trial-Application-to-Treat-Autism-Related-Spectrum-Disorders.html?f=22&fvtc=4&fvtv=49683GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders2022-10-07T13:20:00Z<![CDATA[BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics today announced that it has submitted a clinical trial application to the Israel Ministry of Health for approval of a Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy.]]>https://www.globenewswire.com/news-release/2021/12/16/2353817/0/en/GCANRx-Strategic-Advisor-Dr-Adi-Aran-to-be-Interviewed-by-Dr-Sanjay-Gupta-on-CNN-Cannabis-Special.html?f=22&fvtc=4&fvtv=49683GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special2021-12-16T14:35:33Z<![CDATA[The 6th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19th at 9pm ET]]>GCAN Advisor to be Featured in CNN Documentaryweed.6https://www.globenewswire.com/news-release/2021/12/02/2345118/0/en/GCANRx-Appoints-Renowned-Cannabinoid-Researcher-Dr-Adi-Aran-as-Strategic-Advisor.html?f=22&fvtc=4&fvtv=49683GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor2021-12-02T13:52:28Z<![CDATA[Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies.]]>https://www.globenewswire.com/news-release/2021/11/08/2329184/0/en/GCANRx-Announces-Initiation-of-Preclinical-Study-for-Neuropsychiatric-Cannabinoid-Therapy.html?f=22&fvtc=4&fvtv=49683GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy2021-11-08T12:50:00Z<![CDATA[BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has begun the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy.]]>https://www.globenewswire.com/news-release/2021/08/19/2283675/0/en/GCANRx-Signs-Licensing-Agreement-with-Shaare-Zedek-Scientific-for-Innovative-Neuropsychiatric-Cannabinoid-Therapy.html?f=22&fvtc=4&fvtv=49683GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy2021-08-19T13:45:21Z<![CDATA[BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has entered into a licensing agreement (the “Agreement”) with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Shaare Zedek Medical Center, founded in 1901, is one of the largest multidisciplinary research hospitals in Israel with 1,000 beds and over 850,000 patient visits a year. The SZMC Center for Research and Development has over 300 annual publications of investigator initiated studies in medical journals in addition to almost 160 clinical trials.]]>https://www.globenewswire.com/news-release/2021/03/16/2193755/0/en/GCANRx-Announces-Collaboration-with-Renowned-Cannabis-Research-Lab.html?f=22&fvtc=4&fvtv=49683GCANRx Announces Collaboration with Renowned Cannabis Research Lab2021-03-16T13:12:14Z<![CDATA[BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is proud to announce a collaboration with Israel-based cannabis lab, Phytor LTD, a leader in the research and development of plant-based therapeutics.]]>https://www.globenewswire.com/news-release/2021/03/09/2189512/0/en/The-Greater-Cannabis-Company-Announces-Relisting-to-OTCQB.html?f=22&fvtc=4&fvtv=49683The Greater Cannabis Company Announces Relisting to OTCQB2021-03-09T13:00:00Z<![CDATA[BALTIMORE, March 09, 2021 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTCQB: GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market, today announced that shares of its common stock were reinstated for trading on the OTCQB® Venture Market after an OTC Markets compliance review. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosure The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the Securities and Exchange Commission (SEC) as an “established public market” for the purpose of determining the public market price when registering securities for resale with the SEC. The OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements. The majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.]]>